Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05942300 | CPI-0209 Plus Carboplatin in Patients With Platinum Sensitive Recurrent Ovarian Cancer | PHASE1 | RECRUITING | 30 | — | — | Jan 30, 2024 | Dec 31, 2028 | Jun 19, 2025 | 1 | United States |
MTD will be determined via Dose-limiting toxicity (DLT)s defined as any grade 3-4 non-hematological or grade 4 hematological toxicity at least possibly related to the treatment, occurring during the first two cycles of treatment and per Cancer Therapy Evaluation Program (CTEP) Common Terminology Criteria for Adverse Events (CTCAE) version 5.
| Arm | Type | Description |
|---|---|---|
| CPI-0209 (100 mg) + carboplatin | EXPERIMENTAL | CPI-0209: 100 mg (oral dosing) carboplatin administered intravenously as per institutional standards |
| CPI-0209 (150 mg) + carboplatin | EXPERIMENTAL | CPI-0209: 100 mg (oral dosing) carboplatin administered intravenously as per institutional standards |
| Name | Type | Description |
|---|---|---|
| CPI-0209 | DRUG | A second-generation EZH2 inhibitor that has been designed to achieve comprehensive anti-cancer target coverage through extended on-target residence time. |
| carboplatin | DRUG | Carboplatin is a chemotherapy drug that contains the metal platinum. It stops or slows the growth of cancer cells and other rapidly growing cells by damaging their DNA. |
Inclusion Criteria: * Patients with platinum-sensitive recurrent ovarian, fallopian or primary peritoneal cancer (defined as recurrent disease \> 6 months after completing last platinum- based chemotherapy) that are eligible to receive platinum-based chemotherapy). * Documented disease recurrence/p...